New York State Teachers Retirement System Has $453,000 Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

New York State Teachers Retirement System reduced its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 71.2% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,678 shares of the biopharmaceutical company's stock after selling 4,158 shares during the quarter. New York State Teachers Retirement System's holdings in Alnylam Pharmaceuticals were worth $453,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Whipplewood Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 208.8% in the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the period. Bessemer Group Inc. increased its stake in Alnylam Pharmaceuticals by 176.9% during the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 69 shares during the period. Larson Financial Group LLC increased its stake in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares during the period. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $28,000. Finally, Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Trading Down 2.4%

Shares of ALNY traded down $7.70 during midday trading on Friday, hitting $314.94. The stock had a trading volume of 1,081,877 shares, compared to its average volume of 855,444. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $333.70. The business has a 50-day simple moving average of $301.17 and a two-hundred day simple moving average of $268.95. The firm has a market cap of $41.07 billion, a P/E ratio of -150.69 and a beta of 0.23. The company has a current ratio of 3.04, a quick ratio of 2.98 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to analyst estimates of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business's quarterly revenue was up 20.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) earnings per share. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have commented on ALNY. Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Scotiabank raised their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Morgan Stanley lowered their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research note on Friday, April 11th. Finally, Jefferies Financial Group raised their target price on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the company a "buy" rating in a research note on Monday, July 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $345.70.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 19,297 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the completion of the sale, the chief executive officer directly owned 48,948 shares in the company, valued at approximately $14,978,088. This trade represents a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.